对于接受脏移植的接受者来说GLP-1受体激活剂
Sarah H Schmitz1, Babak J Orandi2,3
1Weill Cornell Medicine Department of Medicine, Comprehensive Weight Control Center; New York, NY, USA.
概括
类似葡萄糖类-1受体激动剂对脏移植接受者来说是有前途的,为血糖控制和体重提供好处. 虽然通常是安全的,但胃肠道副作用和有限的数据需要仔细选择患者和进一步研究.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 接受移植 (KTR) 的人往往患有超重,肥胖和移植后糖尿病,增加心血管和风险.
- 类似葡萄糖类-1受体激动剂 (GLP-1RAs) 在一般人群中显示出对血糖控制,减肥和心保护的有效性.
- 关于GLP-1RA在KTR中使用的数据有限,需要对当前证据和未来研究方向进行审查.
研究的目的:
- 审查GLP-1RAs在移植接受者的理由,安全性和有效性.
- 总结在KTR中使用GLP-1RAs的临床考虑因素,包括患者选择和监测.
- 确定当前证据的局限性,并提出未来的研究重点.
主要方法:
- 叙述性综述综合了非移植群体最近试验的数据和KTRs中新出现的现实世界的证据.
- 关于GLP-1RA在移植后环境中的安全性和有效性的回顾性和前性研究的摘要.
- 对临床考虑的分析,包括剂量升级和副作用管理.
主要成果:
- GLP-1RAs在KTR中似乎一般耐受良好,没有明显增加移植排斥,胰腺炎或免疫抑制药物相互作用的风险.
- 胃肠道副作用和早期停止治疗是常见的,需要量身定制的咨询和剂量定位.
- 目前的证据受限于样本规模小,随访时间短,以及潜在的选择偏差,影响安全性和有效性的确定性.
结论:
- GLP-1RAs代表了对KTR的有前途的治疗选择,解决了常见的并发病症.
- 仔细选择患者,剂量定位和咨询对于管理副作用和改善患者的坚持是必不可少的.
- 进一步的高质量研究,包括随机试验,对于确认长期的移植和患者结果以及优化GLP-1RA在KTR中的使用至关重要.
相关概念视频
01:24Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
01:26Kidney Transplant II: Surgical Procedure
320
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
320
01:28Kidney Transplant I: Introduction
343
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
343
01:06Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
01:16Kidney Transplant III: Nursing Management
318
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
318
01:23Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594